Press Release 18 May 2022 Autobahn Therapeutics Announces Emerging Preclinical Data Demonstrating Ability of CNS-Delivered Thyromimetics to Promote Remyelination by autobahntx Read More
Press Release 18 May 2022 Autobahn Therapeutics to Present New Preclinical Data at the 2022 American Academy of Neurology Annual Meeting by autobahntx Read More
Press Release 18 May 2022 Autobahn Therapeutics Announces New Preclinical Data Supporting its Novel Brain-Targeting Platform for the Development of Therapeutics for CNS Disorders by autobahntx Read More
Press Release 18 May 2022 Autobahn Therapeutics Strengthens Management Team to Support Advancement of Novel Therapies for CNS Disorders by autobahntx Read More
Press Release 18 May 2022 Autobahn Therapeutics Announces Orphan Drug Designation Granted to ABX-002 for the Treatment of X-linked Adrenoleukodystrophy by autobahntx Read More
Press Release 18 May 2022 Autobahn Therapeutics Acquires Clinical-Stage FAAH Inhibitor from Astellas, Strengthening its Brain Targeting Chemistry Platform by autobahntx Read More
Press Release 18 May 2022 Autobahn Therapeutics Presents Preclinical, Proof of Concept Data for ABX-002 for the Treatment of Adrenomyeloneuropathy by autobahntx Read More
Press Release 18 May 2022 Autobahn Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference by autobahntx Read More
Press Release 18 May 2022 Autobahn Therapeutics Strengthens its Team to Support its Continued Growth by autobahntx Read More
Press Release 18 May 2022 Autobahn Therapeutics Completes Successful Pre-IND Meeting with FDA by autobahntx Read More
News 18 May 2022 Sehr gut: Autobahn roars out of stealth mode with $76M, new leitmotif in MS by autobahntx Read More
News 18 May 2022 ARCH-backed Autobahn launches with $76M to rebuild myelin and reverse MS by autobahntx Read More
Press Release 18 May 2022 Autobahn Therapeutics Launches with $76 Million Series B Financing to Develop Next Generation Therapies for CNS Disorders by autobahntx Read More